Literature DB >> 31646554

PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.

X-L Liu1, H-M Liu, N Han, F-H Li, F Sun, D-M Fan, Q Xu.   

Abstract

OBJECTIVE: The aim of this study was to clarify the potential role of PCAT1 in the occurrence and development of ovarian cancer (OC). PATIENTS AND METHODS: Expression levels of PCAT1 and NEK2 in OC tissues and cell lines were detected by quantitative Real-time polymerase chain reaction (qRT-PCR). Correlation between PCAT1 expression with tumor stage and prognosis of OC patients was analyzed. Knockdown or over-expression of PCAT1 and NEK2 were achieved by siRNA or lentivirus transfection, respectively. Subsequently, cell viability, apoptosis, cell cycle progression and migration were determined by cell counting kit-8 (CCK-8), flow cytometry and transwell assay, respectively. Furthermore, the protein levels of relative genes in Wnt pathway were detected by Western blot.
RESULTS: PCAT1 was highly expressed in OC tissues and cell lines, especially in tumor tissues with stage III-IV compared with stage I-II. The prognosis of OC patients with higher expression of PCAT1 was significantly worse than those with lower expression. In vitro experiments confirmed that PCAT1 knockdown obviously inhibited proliferative and migratory potentials, whereas induced apoptosis of OC cells. No significant changes were observed in cell cycle progression of OC cells after knockdown or overexpression of PCAT1. Meanwhile, overexpression of PCAT1 remarkably upregulated the expression level of NEK2, which was the target gene of PCAT1. Interestingly, NEK2 knockdown could obviously suppress cell migration. Furthermore, Western blot results elucidated that PCAT1 knockdown could inhibit the protein levels of relative genes in Wnt pathway in OC cells.
CONCLUSIONS: PCAT1 was highly expressed in OC tissues than adjacent normal tissues. PCAT1 overexpression significantly promoted proliferative and migratory potentials, whereas inhibited apoptosis of OC cells through upregulating NEK2 expression via Wnt pathway.

Entities:  

Year:  2019        PMID: 31646554     DOI: 10.26355/eurrev_201910_19133

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

1.  Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Authors:  Zeyu Xing; Menglu Zhang; Xin Wang; Jiaqi Liu; Gang Liu; Kexin Feng; Xiang Wang
Journal:  J Mol Histol       Date:  2021-05-19       Impact factor: 2.611

Review 2.  Flaming the fight against cancer cells: the role of microRNA-93.

Authors:  Milad Ashrafizadeh; Masoud Najafi; Reza Mohammadinejad; Tahereh Farkhondeh; Saeed Samarghandian
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

Review 3.  The Oncogenic Potential of the Centromeric Border Protein FAM84B of the 8q24.21 Gene Desert.

Authors:  Yan Gu; Xiaozeng Lin; Anil Kapoor; Mathilda Jing Chow; Yanzhi Jiang; Kuncheng Zhao; Damu Tang
Journal:  Genes (Basel)       Date:  2020-03-15       Impact factor: 4.096

4.  Transcriptome analysis of the effect of a novel human serine protease inhibitor SPINK13 on gene expression in MHCC97-H cells.

Authors:  Ling Wei; Tao An; Yunhe An; Zheng He; Tingting Jia; Baoming Li; Yongzhi Lun
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

5.  Baseline lncRNA PCAT1 high expression and its longitude increment during induction therapy predict worse prognosis in multiple myeloma patients.

Authors:  Peng Zhao; Xiaohong Zhao
Journal:  J Clin Lab Anal       Date:  2021-09-26       Impact factor: 2.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.